QYM1 / Qymune - LARVOL DELTA

Potent B-Cell Depletion with Zero Cytokine Release via a Novel αβTCR-Directed T-Cell Engager for Autoimmune Therapy (ACR Convergence 2026) - "QYM1 represents a first-in-class T-cell engager that successfully decouples targeted cytotoxicity from cytokine release, establishing an exceptionally wide therapeutic window with potent B-cell depletion and zero cytokine secretion. This preclinical study demonstrates that QYM1 favorable safety profile allows for full therapeutic dosing from the very first administration, bypassing the need for step-up mitigation protocols, thereby maximizing clinical efficacy and presenting a safe, off-the-shelf option for an expanded pool of patients suffering from moderate as well as severe autoimmune diseases."

Immunology • Inflammatory Arthritis • IFNG • IL1B • IL6 • TNFA